This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GenVec Financing Sinks Shares: BioBuzz

GAITHERSBURG, Md. ( TheStreet) -- Shares of GenVec (GNVC - Get Report) are down 23% Wednesday after the tiny drug maker said it had sold 14 million shares of stock and another 4.2 million warrants, raising net proceeds of $26.2 million.

The GenVec offering of units consisting of stock and warrants, priced at $2 per unit, comes predictably after a run in GenVec's stock price, which has essentially doubled since December. The stock closed Tuesday at $2.47. In recent trading, shares were down to $1.88.

Biotech, especially small-cap biotechs, do one thing exceptionally well -- raise money. Investors take note.

"Dilution is the name of the game after big runs in the market, especially in a market place where all small bios are raising cash as a group," says JohnWelshPhd, a savvy trader, including of small-cap biotech stocks, who I follow on Twitter.

When news of the GenVec offering broke, JohnWelshPhd tweeted, "Surprise factor zero."

So true.

Now, the $26 million dollar question is whether Wednesday's financing implies anything about the upcoming interim analysis of the phase III study of TNFerade in pancreatic cancer.

Is GenVec simply being opportunistic about raising money ahead of this important, potentially stock-moving event? Or, is the company fearful that the TNFerade results will be negative, so it's getting the money now while it can?

No one but GenVec knows the answer, of course, and executives aren't about to tell us. When Cell Therapeutics (CTIC - Get Report) raised money a couple of weeks ago, just before the FDA advisory panel for its lymphoma drug pixantrone, I wrote that that it presaged bad things for the drug.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $0.50 -4.20%
GNVC $0.78 -1.28%
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs